Skip to main content

TNF inhibitor

    RT @ejdein1: The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow
    3 years 6 months ago
    The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow
    RT @ejdein1: More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Ev
    3 years 6 months ago
    More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX
    RT @doctorRBC: Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs
    3 years 6 months ago
    Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest
    RT @KDAO2011: Dr. Weinblatt dodges the question which TNFi prefers after MTX-IR. Which one do you choose? #ACR20 #GreatD
    3 years 6 months ago
    Dr. Weinblatt dodges the question which TNFi prefers after MTX-IR. Which one do you choose? #ACR20 #GreatDebate @RheumNow
    Dr. Vibeke Strand previews ACR 2020 highlights, including The Great Debate

    Dr. Vibeke Strand discusses opening day at ACR 2020, sessions she's looking forward, and provides a sneak peek into The Great Debate. 

    The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in…